159 related articles for article (PubMed ID: 11775603)
1. Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease. 2000.
Fraix V; Pollak P; Van Blercom N; Xie J; Krack P; Koudsie A; Benabid AL
Neurology; 2001 Nov; 57(10 Suppl 3):S60-2. PubMed ID: 11775603
[No Abstract] [Full Text] [Related]
2. Direct effect of subthalamic nucleus stimulation on levodopa-induced peak-dose dyskinesia in patients with Parkinson's disease.
Katayama Y; Oshima H; Kano T; Kobayashi K; Fukaya C; Yamamoto T
Stereotact Funct Neurosurg; 2006; 84(4):176-9. PubMed ID: 16905880
[TBL] [Abstract][Full Text] [Related]
3. Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: long-term follow-up.
Tavella A; Bergamasco B; Bosticco E; Lanotte M; Perozzo P; Rizzone M; Torre E; Lopiano L
Neurol Sci; 2002 Sep; 23 Suppl 2():S111-2. PubMed ID: 12548368
[TBL] [Abstract][Full Text] [Related]
4. Optogenetic Inhibition of the Subthalamic Nucleus Reduces Levodopa-Induced Dyskinesias in a Rat Model of Parkinson's Disease.
Yoon HH; Min J; Hwang E; Lee CJ; Suh JK; Hwang O; Jeon SR
Stereotact Funct Neurosurg; 2016; 94(1):41-53. PubMed ID: 26962855
[TBL] [Abstract][Full Text] [Related]
5. Parkinson's disease. A half century of progress.
Jankovic J
Neurology; 2001 Nov; 57(10 Suppl 3):S1-3. PubMed ID: 11771154
[No Abstract] [Full Text] [Related]
6. How L-DOPA was discovered as a drug for Parkinson's disease 40 years ago.
Hornykiewicz O
Wien Klin Wochenschr; 2001 Nov; 113(22):855-62. PubMed ID: 11762121
[No Abstract] [Full Text] [Related]
7. Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible?
Bejjani BP; Arnulf I; Demeret S; Damier P; Bonnet AM; Houeto JL; Agid Y
Ann Neurol; 2000 May; 47(5):655-8. PubMed ID: 10805339
[TBL] [Abstract][Full Text] [Related]
8. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease.
Krack P; Batir A; Van Blercom N; Chabardes S; Fraix V; Ardouin C; Koudsie A; Limousin PD; Benazzouz A; LeBas JF; Benabid AL; Pollak P
N Engl J Med; 2003 Nov; 349(20):1925-34. PubMed ID: 14614167
[TBL] [Abstract][Full Text] [Related]
9. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours.
Lhommée E; Klinger H; Thobois S; Schmitt E; Ardouin C; Bichon A; Kistner A; Fraix V; Xie J; Aya Kombo M; Chabardès S; Seigneuret E; Benabid AL; Mertens P; Polo G; Carnicella S; Quesada JL; Bosson JL; Broussolle E; Pollak P; Krack P
Brain; 2012 May; 135(Pt 5):1463-77. PubMed ID: 22508959
[TBL] [Abstract][Full Text] [Related]
10. Parkinson's disease, subthalamic stimulation, and selection of candidates: a pathological study.
Jarraya B; Bonnet AM; Duyckaerts C; Houeto JL; Cornu P; Hauw JJ; Agid Y
Mov Disord; 2003 Dec; 18(12):1517-20. PubMed ID: 14673889
[TBL] [Abstract][Full Text] [Related]
11. Levodopa: 50 years of a revolutionary drug for Parkinson disease.
Fahn S; Poewe W
Mov Disord; 2015 Jan; 30(1):1-3. PubMed ID: 25488146
[No Abstract] [Full Text] [Related]
12. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease.
Limousin P; Krack P; Pollak P; Benazzouz A; Ardouin C; Hoffmann D; Benabid AL
N Engl J Med; 1998 Oct; 339(16):1105-11. PubMed ID: 9770557
[TBL] [Abstract][Full Text] [Related]
13. Levodopa. Is toxicity a myth? 1998.
Agid Y
Neurology; 2001 Nov; 57(10 Suppl 3):S46-51. PubMed ID: 11775601
[No Abstract] [Full Text] [Related]
14. Deep brain stimulation in Parkinson's disease: opposite effects of stimulation in the pallidum.
Bejjani BP; Damier P; Arnulf I; Papadopoulos S; Bonnet AM; Vidailhet M; Agid Y; Pidoux B; Cornu P; Dormont D; Marsault C
Mov Disord; 1998 Nov; 13(6):969-70. PubMed ID: 9827624
[No Abstract] [Full Text] [Related]
15. Parkinson's disease patients with bilateral subthalamic deep brain stimulation gain weight.
Macia F; Perlemoine C; Coman I; Guehl D; Burbaud P; Cuny E; Gin H; Rigalleau V; Tison F
Mov Disord; 2004 Feb; 19(2):206-12. PubMed ID: 14978678
[TBL] [Abstract][Full Text] [Related]
16. High frequency stimulation of the subthalamic nucleus and levodopa induced dyskinesias in Parkinson's disease.
Obeso JA; Linazasoro G; Guridi J; Ramos E; Rodriguez-Oroz MC
J Neurol Neurosurg Psychiatry; 2000 Jan; 68(1):122-3. PubMed ID: 10671136
[No Abstract] [Full Text] [Related]
17. Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa-intolerant patients.
Katayama Y; Kasai M; Oshima H; Fukaya C; Yamamoto T; Ogawa K; Mizutani T
J Neurosurg; 2001 Aug; 95(2):213-21. PubMed ID: 11780890
[TBL] [Abstract][Full Text] [Related]
18. Milestones in Parkinson's disease therapeutics.
Rascol O; Lozano A; Stern M; Poewe W
Mov Disord; 2011 May; 26(6):1072-82. PubMed ID: 21626552
[TBL] [Abstract][Full Text] [Related]
19. The effect of l-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. 1961.
Birkmayer W; Hornykiewicz O
Wien Klin Wochenschr; 2001 Nov; 113(22):851-4. PubMed ID: 11763859
[No Abstract] [Full Text] [Related]
20. [L-dopa: a fascinating history].
García de Yébenes J; García Ruiz P
Neurologia; 1998; 13 Suppl 1():36-40. PubMed ID: 9859684
[No Abstract] [Full Text] [Related]
[Next] [New Search]
